Baldwin Wealth Partners LLC MA Decreases Stake in Johnson & Johnson $JNJ

Baldwin Wealth Partners LLC MA lowered its position in Johnson & Johnson (NYSE:JNJ) by 3.0% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 71,686 shares of the company’s stock after selling 2,232 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Johnson & Johnson were worth $10,950,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. GFG Capital LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $35,000. Highline Wealth Partners LLC increased its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $48,000. Finally, von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Citigroup lifted their target price on Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $192.94.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE JNJ opened at $190.66 on Friday. The business has a 50-day moving average of $178.48 and a 200-day moving average of $163.77. The firm has a market capitalization of $459.16 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.